We are monitoring the impact of COVID-19 on North America Cancer Metabolism Based Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 7867
Share on
Share on

North America Cancer Metabolism Based Therapeutics Market Research Report – Segmented By Therapy, Drug Type, Indication & Country (The United States, Canada and Rest of North America) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 7867
Pages: 145

North America Cancer Metabolism Based Therapeutics Market Size (2021 to 2026)

The size of the North America Cancer Metabolism Based Therapeutics market is anticipated to grow at a healthy rate during the forecast period. As the number of people who have pancreatic cancer is high in North America, the North America Cancer Metabolism Based Therapeutics Market dominates the Global Market.

Growth in the R & D activities for the target-based therapies, Y-O-Y growth in the cancer incidence, growing awareness regarding the cancer symptoms, and the treatment procedures are expected to drive the market growth in North America. A growing number of strategic and research collaborations have been inscribed among the companies in developing research activities in this region.         

High treatment costs associated with the related therapeutics are expected to restrain market growth. According to the American Cancer Society, pancreatic cancer proceeds for 3% of all cancers and across 7% of all cancer deaths in the U.S. Also, the risk of harmful side effects associated with cancer drug therapies and its use may produce adverse outcomes, which may hamper the market growth in this region.

This research report on the North America Cancer Metabolism Based Therapeutics market has been segmented & sub-segmented into the following categories:

By Therapy:

  • Biological Drug Therapies  
  • Targeted Drug Therapies  

By Drug Type:

  • Enasidenib        
  • CPI-613   
  • Other Drugs    

By Indication:

  • Melanoma              
  • Myelodyspalstic Syndrome (MDS)
  • Acute Myeloid Leukemia (AML)    
  • Metastatic Renal Cell Carcinoma    
  • Others     

Around twenty-one thousand cases of Acute Myeloid Leukaemia attacks were reported by the American Cancer Society in 2018, out of which 50% are experiencing the terminal stage. Many non-profit organizations came into the picture to help people. They increased awareness about pancreatic cancer symptoms and the treatment process, allowing the market to increase its size.

By Country:

  • The United States
  • Canada
  • Rest of North America

Regional Analysis:

North America is expected to dominate with the US and Canada's largest share as major contributing countries. The market is attributed to the rise in the population diagnosed with cancer every year, the increase in the aging population, and body exposure to various radiations. Also, inventing new strategies in treating cancer among the patients is anticipated to have high market growth. 

The United States is leading and ruling the cancer metabolism-based therapeutics market during the forecasting framework. Increasing cancer, the surge in advances in therapies, and commodification of new bio-similar factors propel market growth. Smoking tobacco, alcohol intake, physical inactivity, low diet, obesity, and air pollution in urban areas, growing the latest technologies in treating cancer cells, are likely to boost the cancer metabolism-based therapeutics market growth in this region. Favorable government regulations towards cancer therapies and an increase in the growing demand for personalized medicine, together with the capability of existing economies that offer profitable opportunities in the market, are factors accelerating the market in this region. US market is driven by factors like growth in per capita income and rapid augmentation in the bio-medicine domain in the cancer metabolism-based therapeutics market growth in North America.

Some of the prime manufacturers of Cancer Metabolism Based Therapeutics in North America are AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapy                       

                                5.1.1 Introduction           

                                5.1.2 Biological Drug Therapies  

                                5.1.3 Targeted Drug Therapies  

                                5.1.4  Y-o-Y Growth Analysis, By Therapy              

                                5.1.5  Market Attractiveness Analysis, By Therapy            

                                5.1.6  Market Share Analysis, By Therapy             

                5.2 Drug Type                   

                                5.2.1 Introduction           

                                5.2.2 Enasidenib              

                                5.2.3 CPI-613     

                                5.2.4 Other Drugs            

                                5.2.5 Y-o-Y Growth Analysis, By Drug Type           

                                5.2.6 Market Attractiveness Analysis, By Drug Type         

                                5.2.7 Market Share Analysis, By Drug Type          

                5.3 Indication                    

                                5.3.1 Introduction           

                                5.3.2 Melanoma              

                                5.3.3 Myelodyspalstic Syndrome (MDS)

                                5.3.4 Acute Myeloid Leukemia (AML)    

                                5.3.5 Metastatic Renal Cell Carcinoma    

                                5.3.6 Others      

                                5.3.7 Y-o-Y Growth Analysis, By Indication           

                                5.3.8 Market Attractiveness Analysis, By Indication         

                                5.3.9 Market Share Analysis, By Indication           

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapy

                                                6.1.3.3 By Drug Type

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapy

                                                6.1.4.3 By Drug Type

                                                6.1.4.4 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Therapy

                                                6.1.5.3 By Drug Type

                                                6.1.5.4 By Indication

                6.2 United States                            

                6.3 Canada                         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 AstraZeneca                               

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis                       

                8.3 Celgene                       

                8.4 Rafael Pharmaceuticals                         

                8.5 Cornerstone Pharmaceuticals                            

                8.6 Polaris Group                             

                8.7 Agios Pharmaceuticals                           

                8.8 Taiho Pharmaceuticals                           

                8.9 3-V Biosciences                         

                8.10 Calithera Biosciences                           

                8.11 BERG Health                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Therapy, by  Drug type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. North America Cancer Metabolism Based Therapeutics Market, By Therapy, From 2021 to 2026 (USD Million)
  2. North America Biological Drug Therapies Market, By Region, From 2021 to 2026 (USD Million)
  3. North America Targeted Drug Therapies   Market, By Region, From 2021 to 2026 (USD Million)
  4. North America Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2021 to 2026 (USD Million)
  5. North America Enasidenib         Market, By Region, From 2021 to 2026 (USD Million)
  6. North America CPI-613 Market, By Region, From 2021 to 2026 (USD Million)
  7. North America Other Drugs Market, By Region, From 2021 to 2026 (USD Million)
  8. North America Cancer Metabolism Based Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  9. North America Melanoma Market, By Region, From 2021 to 2026 (USD Million)
  10. North America Myelodyspalstic Syndrome (MDS) Market, By Region, From 2021 to 2026 (USD Million)
  11. North America Acute Myeloid Leukemia (AML) Market, By Region, From 2021 to 2026 (USD Million)
  12. North America Metastatic Renal Cell Carcinoma Market, By Region, From 2021 to 2026 (USD Million)
  13. North America Others       Market, By Region, From 2021 to 2026 (USD Million)
  14. United States Cancer Metabolism Based Therapeutics Market, By Therapy, From 2021 to 2026 (USD Million)
  15. United States Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2021 to 2026 (USD Million)
  16. United States Cancer Metabolism Based Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  17. Canada Cancer Metabolism Based Therapeutics Market, By Therapy, From 2021 to 2026 (USD Million)
  18. Canada Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2021 to 2026 (USD Million)
  19. Canada Cancer Metabolism Based Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample